Text this: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

  _  _     ______    ____      _____      _____  
 | \| ||  /_   _//  |  _ \\   |  ___||   / ___// 
 |  ' ||   -| ||-   | |_| ||  | ||__     \___ \\ 
 | .  ||   _| ||_   | .  //   | ||__     /    // 
 |_|\_||  /_____//  |_|\_\\   |_____||  /____//  
 `-` -`   `-----`   `-` --`   `-----`  `-----`